Helioson’s molecular glue and PROTAC have been selected for preclinical studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting and will be presented as Late-Breaking abstracts.

About AACR

    The AACR Annual Meeting, one of the largest oncology research conferences globally, highlights forefront research and clinical progress in oncology, attracting interest from cancer researchers worldwide. The event is scheduled to take place from April 25th to 30th, 2025, in Chicago, IL, USA.

Title: HP-001: A highly potent IKZF1/3 degrader that demonstrates superior safety profile

Category: Late-Breaking

Presentation Number: LB235 (section 54)

Session Time: April 28, 2025, 2:00 PM - 5:00 PM

Link: https://www.abstractsonline.com/pp8/#!/20273/presentation/10059

Title: HP-002: A brain-penetrant PROTAC that demonstrated potent anti-proliferation activities on multiple BTK mutant

Category: Late-Breaking

Presentation Number: LB236 (section 54)

Session Time: April 28, 2025, 2:00 PM - 5:00 PM

Link: https://www.abstractsonline.com/pp8/#!/20273/presentation/10060

Title: Preclinical profiling of CY002-243-1: A highly potent PDE3A-SLFN12 molecular glue for cancer therapy

Category: Late-Breaking

Presentation Number: LB423 (section 51)

Session Time: April 30, 2025, 9:00 AM - 12:00 PM

Link: https://www.abstractsonline.com/pp8/#!/20273/presentation/10011

About Helioson

    Shanghai Helioson Pharmaceutical Co., Ltd. was established in Oct. 2021, located in Pujiang Smart Plaza, Minhang District, Shanghai. The company is dedicated to developing innovative drugs with the focus on clinical value and in-depth insight into disease mechanisms. Relying on the cutting-edge technology platforms (Protein Steady-state and CADD) to drive the development of differentiated and globally-valuable drugs, Helioson’s pipeline comprises a growing number of molecular glue /PROTAC programs on oncology and auto-immune diseases.